

LIDDS participates in LSX World Congress and ERLIG Therapeutic Oligo meetings

UPPSALA, SWEDEN – LIDDS AB (publ) announces today that the company will participate in two important events in the coming weeks. Firstly, the LSX World Congress, taking place in London between 3 and 4 May 2023. Secondly, ELRIG Therapeutic Oligo and European Chemical Biology symposium, taking place at AstraZeneca in Gothenburg between 9 and 11 May 2023.

LIDDS's CEO Anders Månsson, and CSO Matthew Lindon will participate in the **LSX World Congress**, which is physically organized in London, UK. The LSX meeting is focused on partnering, strategy & investment for life science executive leaders. The meeting provides LIDDS with more opportunities for both collaboration and partner discussions. LIDDS's attendance will be in conjunction with our on-going partnership with Alira Health to drive forward our business development activities.

LIDDS's CSO, Matthew Lindon will attend **ELRIG Therapeutic Oligo and European Chemical Biology symposium**, taking place at AstraZeneca in Gothenburg, where he has been accepted to present a poster on LIDDS's Nanoimod project. This poster showcases LIDDS's work to successfully formulate an oligonucleotide therapeutic in NanoZolid® and highlights the pre-clinical work supporting progressing this asset into Phase I clinical studies.

For additional information, please contact


Anders Månsson, CEO Phone: +46 (0)70 860 47 38

E-mail: anders.mansson@liddspharma.com

Jenni Björnulfson, CFO Phone: +46 (0)70 855 38 05

E-mail: jenni.bjornulfson@liddspharma.com

LIDDS's Certified Adviser is Redeye AB





LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

Attachments

LIDDS participates in LSX World Congress and ERLIG Therapeutic Oligo meetings